Healthcare Revenue Generation

Healthcare enterprises don’t convert pilots lightly. We ran multiple enterprise pilots with teams. This time, each one moved forward. That outcome says more than any sales deck. In healthcare, that’s rare. These organizations don’t take risks on unproven vendors. The problem we solve: Revenue leakage from under-coding, missed guidelines, and inconsistent documentation still impacts a meaningful share of claims. Appeals are manual, slow, and dependent on tribal knowledge. Compliance risk limits how aggressively teams can act. We automated the hard parts. Ember audits 100% of claims, surfaces defensible coding opportunities, and automates appeal workflows with traceable logic and citations. Customers recover revenue while staying compliant. What changed: We partnered with state-level hospital associations and leading national medical centers. These teams demand domain expertise, auditability, and non-negotiable compliance. We delivered all three. Five additional enterprise pilots are now in motion, with near-term revenue already in flight. Why 100% converted: We built like people who sat in the chair. Our platform handles complex coding reviews, guideline interpretation, and appeal preparation, the work that normally slows teams down or never gets done. When the product actually reduces risk and drives revenue, pilots don’t churn. They expand. The takeaway: Enterprise conversion isn’t about sales tactics. It’s about building so close to the problem that proof becomes undeniable. For healthcare founders building enterprise products: What metric actually predicted your pilot-to-paid conversion?

The Hospital Paradox: Why Indian Healthcare Giants Profit Despite Empty Beds A sector where patients are told “no beds available” while hospitals report just 65% occupancy. Sounds like inefficiency? It’s actually a strategy. And it’s reshaping Indian healthcare economics. ✅ The Hard Numbers: ARPOB is the Real Metric Even with empty beds, hospital chains are delivering record revenue per occupied bed (ARPOB): 1. Max Healthcare: Rs 78000/day 2. Fortis Healthcare: Rs 73000/day 3. Medanta: Rs 67000/day 4. Apollo Hospitals: Rs 62000/day That’s 15–20% YoY growth, despite flat occupancy. ✅ The Business Shift: From Volume to Value A) High-Margin Procedures First: Cardiac surgeries: Rs 3–15 lakh each, oncology cycles: Rs 2–20 lakh, organ transplants: Rs 8–25 lakh & complex neurosurgeries: Rs 5–18 lakh. One cardiac surgery = revenue of 50 general medicine admissions. B) Bed Mix Strategy: ICU beds: 25–30% of capacity (vs 15% norm), Super specialty wards: 40–45% & General wards: cut to 25–30%. ICU beds bring 3–5x more revenue than general beds. ✅ Ripple Effects Across Sectors A) Stocks: Apollo up 180% in 24 months, Max market cap jumped from Rs 8k cr to Rs 22k cr & Fortis revenue up 23% YoY. B) Insurance: Claims rose 31% in FY23, Avg claim: Rs 67k (up from Rs 45k), and premiums hiked 15–25% C) Medical Tourism: 12–15% of revenue from foreign patients, ARPOB for them: Rs 1.2 lakh/day. ✅ The Unseen Layer: Capacity Illusion A) Hospitals keep occupancy “low”: To handle emergency surges, maintain exclusivity, optimise staff for high-value units. B) Tech-Driven Pricing Power: Robotic surgeries: 40–60% premium, New imaging: 25% higher scan revenue & AI diagnostics: 20–30% fee premium. C) Two-Tier Model Emerging: Tier 1: Premium, complex, high-margin hospitals, and Tier 2: Volume-driven routine care providers. ✅ Metro vs Tier-2 Divide A) Metros: ARPOB Rs 65k–80k, 68–72% occupancy, 18–22% foreign patients. B) Tier-2: ARPOB Rs 35k–45k, 58–63% occupancy, domestic tourism focus. The Results A) Healthcare inflation: 12–15% annually, way above general inflation. B) Specialist premium: Salaries 200–300% higher than GPs, deepening talent gaps. C) Expansion paradox: Apollo alone added 1200 new premium beds in FY23, even with “empty” general ones This means more pending patients, longer waits for routine care, rising out-of-pocket bills & quality concentrated in urban hubs. Hospitals are now high-growth, not utilities & premium valuations are justified by margin gains. Let me share #Rajsperspectives 1. The healthcare model is shifting to profitability-first, accessibility-later. 2. Empty beds aren’t inefficiency; they’re deliberate capacity engineering. 3. ARPOB is the new heartbeat of Indian hospital economics. Can India balance profit-driven healthcare with the social responsibility of keeping essential services accessible? Do you think healthcare should follow market logic like any other business? #healthcare #india #economy #hospitals #policy #health

DTC brands chase one-time sales and wonder why they can’t scale past $10M. Hims & Hers took a different approach and built a subscription healthcare powerhouse that’s now projecting $2.4B in 2025 revenue. Bookmark their exact playbook to implement into your brand THE MULTI-SPECIALITY ENGINE Instead of focusing on men’s hair loss, Hims & Hers built the “Netflix of Healthcare.” They bundled multiple specialties under one platform: 👉 Sexual health 👉 Mental health services 👉 Dermatology treatments 👉 Weight loss solutions They systematically expanded within their existing customer base. THE WEIGHT LOSS PIVOT When GLP-1 drugs like Ozempic became mainstream, Hims & Hers saw an opportunity to build relationships. Their clinical data proves: 1️⃣ 75% treatment adherence rate 2️⃣ Average 20.9 lbs lost in 6 months 3️⃣ 10.3% of initial body weight reduction When the FDA ended semaglutide shortages and threatened their compounded drug business, they didn’t panic. Instead, they negotiated a strategic partnership with Novo Nordisk for branded Wegovy access at $199/month vs. $1000+ retail pricing. THE CUSTOMER ACQUISITION FUNNEL Their funnel architecture is textbook: TOF: Super Bowl ads and social media campaigns that grab attention and normalize telehealth conversions. MOF: On-platform assessments with transparent pricing that remove traditional healthcare friction. BOF: Subscription retention through ongoing diagnostics and medication adherence support. Resulting in $110.8M in deferred revenue. THE FINANCIAL  PROOF POINTS Execution metrics are where the strategy meets reality: 👉 2024 revenue: $1.48B, being a 69% YoY increase 👉 Q1 2025 revenue: $586M, being a 111% YoY growth 👉 2025 projected: $2.3-2.4B total revenue Weight loss is projected to generate $725M in 2025. THE LESSON HIDING IN PLAIN SIGHT Hims & Hers didn’t just ride the telehealth wave; they engineered their own current. They scaled by solving real problems with real solutions. Healthcare is about ongoing relationships, not one-time transactions. 

𝗙𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗜𝗢𝘀 𝗪𝗿𝗲𝘀𝘁𝗹𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗥𝗢𝗜: 𝗪𝗵𝗮𝘁 𝗛𝗲𝗹𝗽𝗲𝗱 𝗠𝗲 𝗧𝗲𝗹𝗹 𝘁𝗵𝗲 𝗦𝘁𝗼𝗿𝘆 Let’s be honest, justifying tech investments in healthcare is hard. We see the burnout. We hear the provider feedback. We know the gaps. But when it’s time to sit across the table from finance and explain the return on something like ambient listening, we often fall back on soft wins: • It saves note time • Pajama time is down • Providers like it All true. All important. But not always enough. Over the past few months, I’ve talked with several CIOs some just beginning their ambient journey, others mid-rollout. And most asked the same thing: How do I actually quantify the ROI? At Reid, we’ve started to build a different kind of ROI story. One that ties soft wins to harder outcomes, like revenue cycle lift, physician retention, and net financial value. Ambient documentation is just one use case, but a powerful one. We built a framework that moves the conversation from “this feels helpful” to: • Here’s the payback period • Here’s the dollar impact • Here’s what happens if we scale it And we kept it conservative because it needs to hold up. A few lessons from the process: ✅ Time savings are just the start Cutting 10 to 12 minutes per note adds up fast. At 13,000+ notes a month, that alone could represent over $𝟰𝗠 𝗽𝗲𝗿 𝘆𝗲𝗮𝗿. ✅ Revenue cycle lift is the real multiplier Even a 1% improvement in Level 4 to Level 5 coding, or better HCC documentation accuracy, can 𝘆𝗶𝗲𝗹𝗱 𝘀𝗲𝘃𝗲𝗻-𝗳𝗶𝗴𝘂𝗿𝗲 𝗿𝗲𝘁𝘂𝗿𝗻𝘀. ✅ High performers amplify results Power users don’t just save time, they move faster. Some of our specialty lines saw double- and triple-digit growth. ✅ Retention is underrated Avoiding just two 𝗽𝗵𝘆𝘀𝗶𝗰𝗶𝗮𝗻 𝗱𝗲𝗽𝗮𝗿𝘁𝘂𝗿𝗲𝘀 𝗰𝗼𝘂𝗹𝗱 𝘀𝗮𝘃𝗲 $𝟭𝗠. That’s a real cost avoidance we often overlook. ✅ Pajama time is great. But CFOs want numbers And we have them. We just need to tell the story in their language. If you’re a healthcare CIO trying to measure the impact of any AI initiative or building the case to scale one I’d love to hear what’s working for you. What’s your strategy for telling the ROI story? What’s missing from ours? Let’s compare notes and sharpen the playbook together. #HealthcareCIO #AmbientAI #DigitalHealth #HealthIT #EHR #RevenueCycle #ClinicalEfficiency #AIinHealthcare #CFOReady #TechROI #BurnoutReduction #HealthcareLeadership #PajamaTime #WorkforceWellbeing #PhysicianRetention #Abridge

There are a lot of reasons Ascension's new “Clinical Innovation Institute” gives me pause—anytime a multibillion-dollar health system leads with words like "creativity," "courage," and a "better care experience for all," it’s worth reading between the lines. The area that caught my attention most - $clinical trials$. Why? First, it creates a launch point for venture-backed products that can be tested, validated, and scaled within a captive patient population. It centralizes data collection and infrastructure in a way that enables lucrative licensing deals and opens the door to equity-for-access arrangements with startups, all while allowing Ascension to generate intellectual property and licensing revenue. And it does all of this under a nonprofit umbrella, shielded from taxes, reporting requirements, and the competitive market pressures that would apply to a for-profit enterprise. But one of the more underappreciated aspects—at least outside of pharma and investment circles—is how this kind of infrastructure turns clinical trials into a serious revenue engine. Pharma typically pay between $5,000 and $10,000 per enrolled patient in clinical trials, with a MUCH higher figure for high complexity and rare disease. By streamlining trial infrastructure under the CII they’re effectively acting as an in-house contract research organization (CRO)—and capturing that revenue directly. Sponsors pay more for faster enrollment, centralized contracting, and integrated EHR matching, all of which Ascension now controls systemwide. And that’s just the front-end. The long tail of monetization comes from the data these trials generate which can be packaged, licensed, and sold to support regulatory filings, label expansions, and post-market surveillance. These deals yield 6-7 figure annual contracts. Add in equity stakes negotiated with startups seeking access to their patient population, and this is a venture platform in all but name. And there is IP. The tools, protocols, and AI models co-developed under the auspices of the CII will enable Ascension to claim co-inventor status and generate revenue from licensing. The infrastructure itself—remote recruitment tools, consent workflows, analytics platforms— will likely be spun off entirely as a commercial trial management platform to other systems. None of this is inherently unethical. But when a tax-exempt system acts like a platform company—monetizing patient access, data, and clinical labor—it deserves scrutiny. Especially when the returns rarely reach the communities or care teams that create the value. The CII may improve clinician experience and patient care—but it also looks like a revenue engine built on research and access. When that many financial incentives are layered into the care environment, it is difficult to separate clinical decisions from commercial strategy—we should watch closely? https://lnkd.in/e7WMDx4F

Today: Therapy is a "cost center" in hospitals. Tomorrow: Therapy will be a strategic asset driving financial performance. The TEAM Model is about to flip the script on hospital economics. Here's why 👇 Currently, when a therapist provides services in the hospital: Their salary comes out of the fixed DRG payments More therapy and more therapists on staff 🟰 lower revenue for the hospital -Early mobility programs are an expense, not an investment -Length of stay is the hospital's primary financial driver Under TEAM, when therapists help patients avoid unnecessary post-acute care: -Every day not spent in a SNF saves ~$500-800, reducing the likelihood the hospital will owe CMS for utilization above the anticipated episodic target price -Early and appropriate mobility becomes a revenue-generating strategy -Hospital leadership will track the ROI on early and frequent therapy interventions for patients who need therapy, and not just mobility -Downstream utilization and outcomes matter as much as length of stay This isn't just a minor adjustment - it's a fundamental realignment of incentives. 🌅 The best hospitals will recognize this shift and invest accordingly in: -Ensuring therapists' roles leverage the skills only they can provide -Advanced mobility programs staffed by ancillary staff such CNAs and PT aides, but developed by a strategic team led by the therapy department -Better discharge planning resources deployed more strategically -"Why not home?" as the starting point for creating discharge plans -Post-discharge follow-up systems that prioritize accurate and specific communication between sites of care, with the "warm hand-off" as the gold standard We're witnessing the beginning of a paradigm shift in how hospitals view therapy services. These five TEAM episode types may be the beginning of a "DRG plus 30" structure for acute care episodic accountability and payment. Have you thought about how to leverage the rehab department for TEAM success? #HealthcareEconomics #ValueBasedCare #TEAM #PhysicalTherapy #FutureOfHealthcare

The numbers coming out of the healthcare sector right now are sobering. The American Hospital Association’s 2026 Costs of Caring report, released in March 2026, found that hospitals spent $43B in 2025 trying to collect payments insurers owe for care already delivered, through prior authorization battles, claims denials, and repeated documentation requests. Workforce costs rose 5.6% year over year. And about 56% of hospital costs are tied to service lines where reimbursement falls short of the cost of delivering care, including behavioral health, obstetrics, infectious disease, and burns and wounds. Strata Decision Technology’s Trends report, published in March 2026 and drawing on data from more than 1,900 hospitals, found that many health system operating margins turned negative to start the year, falling to negative 0.6% in January as revenue declines outpaced expense reductions. When the financial picture looks like this, the instinct in most firms is to cut. Reduce headcount, defer capital, renegotiate vendor contracts, tighten supply chain. These are legitimate levers. But they are also finite. And they tend to produce one cycle of savings before the structural problem reasserts itself. The organizations finding durable margin improvement in this environment have generally done something different. They’ve gone looking for the revenue that was already theirs but was being lost in operational friction. According to a McKinsey study published in January 2026, using AI to enable the revenue cycle could lead to a 30 to 60% reduction in cost to collect, faster cash realization, and a workforce refocused on patient value rather than administrative tasks. Health systems collectively spend more than $140B annually on revenue cycle management, with manual processes, fragmented vendor landscapes, and outdated technologies contributing to high costs, delays, and errors. Nearly 20% of claims are denied on average, and as many as 60% of those denied claims are never appealed, representing millions of dollars in lost revenue per health system. That last number is worth sitting with. Revenue that was earned and never collected is not a cost problem. It is an operational design problem. And operational design problems can be solved without cutting a single service line or eliminating a single clinical role. The question for health system leaders right now is not only how to cut. It is where to look for value that already exists but is currently leaking out of the system through manual workflows, denials that go unchallenged, and administrative friction that compounds with every patient encounter. There is more recoverable value inside most health systems than most financial plans currently assume. Finding it requires a different kind of diagnostic. Where is your organization looking for margin recovery right now? #HealthcareFinance #HealthcareLeadership #RevenueRecovery #AIinHealthcare #CIO #CDO #NGInsights Image: Alexander Grey on Unsplash

After 15+ years as an MD, McKinsey consultant, and health system executive, here's what I believe is the most profitable business model shift happening in healthcare right now. While most health systems are fighting to stay above water - navigating Medicaid cuts, rising labor costs, and margins that leave almost no room for error - a small group of forward-thinking systems is making a different move entirely. They're not cutting their way to stability. They're adding a revenue stream that didn't exist before. Here's the shift: Think of your health system like a major airline. You have thousands of passengers and patients you already serve but your revenue model only captures coaches. Meanwhile, patients are spending billions out-of-pocket every year on faster access, dedicated care, and a premium experience. Almost none of that money flows through traditional health systems. It flows to One Medical. To Hims/Hers. To direct-pay concierge clinics. The opportunity isn't out there somewhere. It's inside your existing patient base and it's going uncaptured. That's the premise behind premium healthcare memberships. And it's why I wrote: 𝗣𝗿𝗲𝗺𝗶𝘂𝗺 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗶𝗻 𝟮𝟬𝟮𝟲: 𝗧𝗵𝗲 𝗡𝗲𝘄 𝗥𝗲𝘃𝗲𝗻𝘂𝗲 𝗠𝗼𝗱𝗲𝗹 𝗳𝗼𝗿 𝗛𝗲𝗮𝗹𝘁𝗵 𝗦𝘆𝘀𝘁𝗲𝗺𝘀. Inside, you'll find: 👉 Why the $99/month membership model generates 100% margin revenue with no new headcount, no new buildings, no CapEx. 👉 How health systems are using white-labeled concierge programs to stop patient defection to digital health competitors. 👉 The 6-month implementation roadmap from contract to live service and what the first-year financials actually look like. This isn't a theoretical framework. It's a model I've built and implemented with health systems across the country. Comment 𝗣𝗥𝗘𝗠𝗜𝗨𝗠 below and I'll send it to your DMs.

The health tech companies generating the most durable revenue right now are not the ones on stage at HIMSS talking about transforming care delivery. They are the ones fixing surgical scheduling, automating prior authorization denials, and reducing staffing variance by shift. Scheduling. Staffing. Compliance. Credentialing. Denial management. Revenue integrity. None of these categories generate exciting TechCrunch coverage. None of them attract the investors who want to "reimagine healthcare." And that is precisely why they work. Operationally boring problems have three characteristics that make them excellent venture bets. The buyer is obvious. The ROI is measurable in weeks, not years. And the switching cost, once embedded, is substantial. A perioperative scheduling tool that recovers 2.3 lost surgical cases per week per facility is worth roughly $1.2 million in annual revenue to that hospital. That is not a pilot conversation. That is a procurement conversation with a clear economic buyer and a quantifiable business case. The companies chasing "care transformation" are still running eighteen-month pilots with innovation teams that have no budget authority. The companies solving scheduling errors are signing three-year contracts with COOs. Boring scales. Ambitious stalls in committee.

I often get this question from investors: can you sell the data? It is a fair question. It is also slightly the wrong one. Monetizing data in healthcare is not about selling a spreadsheet. If your strategy starts with “let’s sell the data,” you are already off track. You monetize data by improving decisions in ways that move revenue, cost, or risk. 1. Increase revenue Data helps identify the right patient profiles and prove measurable outcomes. That strengthens reimbursement discussions and enables value-based contracts. Sword Health, for example, publishes clinical and economic outcomes showing reductions in surgery intent and overall healthcare spend. The asset is not the raw dataset. The asset is the credibility that unlocks employer and payer contracts. 2. Reduce cost If data automates assessments, documentation, reporting, or follow-up, you save time across clinical and operational workflows. Time saved becomes margin. Internally, the right dataset also reduces R&D guesswork. It clarifies which endpoints truly matter and prevents teams from building features that look impressive but do nothing for adoption, reimbursement, or outcomes. AI amplifies this effect. In areas such as drug development, AI models trained on large biological and clinical datasets help prioritize targets, design better trials, and avoid costly dead ends. OWKIN and Formation Bio illustrate it perfectly. 3. Reduce risk Healthcare is largely risk management with a clinical interface. If your data can predict non-responders, flag complications early, and demonstrate consistent real-world performance, you lower the perceived risk for payers, providers, regulators, and leading pharma/biotech/medtech companies. Lower risk makes decisions easier. Easier decisions accelerate deals. Many healthcare startups that appear to be “data companies” are, in fact, risk-reduction companies. Their monetization comes from helping others make safer bets. Great healthcare companies pull all three levers at once. So before building a dataset, you should ask yourself: - What endpoints truly matter clinically and economically? - Who benefits from this insight? - Is this strategic and defensible, or are we collecting data because we can? Eventually, you monetize the advantage created by better decisions.